DEFIANCE - ClotTriever Thrombectomy System versus Anticoagulation Alone for Treating Deep Vein Thrombosis
Led by Inari Medical · Updated on 2026-05-29
300
Participants Needed
64
Research Sites
28 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
Researchers are evaluating treatments for symptomatic unilateral iliofemoral deep vein thrombosis (DVT), comparing the ClotTriever System, a mechanical thrombectomy device, to standard anticoagulation therapy. This prospective, multicenter, randomized controlled trial aims to understand which approach better achieves and maintains vessel openness, tracking clinical outcomes and patient details through six months. About 300 participants will be enrolled and randomly assigned to one of the two treatment groups.
Participants in the ClotTriever Intervention Arm will receive the mechanical thrombectomy procedure using the ClotTriever System. Those in the Conservative Medical Management Arm will receive anticoagulation therapy alone, including approved drugs such as Heparin, Coumadin, Rivaroxaban, or Apixaban. The study involves two main treatment approaches, with monitoring continuing through the six-month follow-up period to assess treatment effects and safety.
During the study, participants will undergo assessments to collect data on demographics, comorbidities, DVT diagnosis, and treatment details. Clinical outcomes will be measured at intervals up to 180 days, focusing on a composite clinical endpoint using a win ratio method and evaluating post-thrombotic syndrome severity. Follow-up visits will monitor health status, treatment adherence, and any complications. The total duration of participation will extend through the six-month post-treatment period.
CONDITIONS
Brief Title
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Proximal lower extremity unilateral deep vein thrombosis involving the common femoral, external iliac, or common iliac veins
Symptom onset within 12 weeks before enrollment
Significant symptoms with a Villalta score greater than 9
Willing and able to provide informed consent
You will not qualify if you...
Bilateral iliofemoral deep vein thrombosis
Prior venous stent in the target venous segment
Congenital anatomic anomalies of the inferior vena cava or iliac veins such as IVC aplasia or hypoplasia
Clot in transit including IVC thrombus extending more than 2 cm into the IVC from the common iliac vein
Symptomatic pulmonary embolism with right heart strain judged unsuitable for DVT intervention
Medical or technical reasons preventing intervention as judged by physician
Severe allergy or thrombocytopenia related to heparin
Severe allergy to iodinated contrast agents that cannot be managed
Hemoglobin less than 8.0 g/dL, INR over 1.7 before warfarin started, or platelets less than 50,000/µl that cannot be corrected
Severe renal impairment with estimated GFR less than 30 ml/min in non-dialysis patients
Inability to receive therapeutic anticoagulation
Uncontrolled severe hypertension (systolic > 180 mmHg or diastolic > 105 mmHg)
Recent DVT interventional procedure within 30 days
Participation in another interfering study
Life expectancy less than 6 months or non-ambulatory status
Unmanageable hypercoagulable states
Conditions judged by investigator to contraindicate participation or affect assessments
Previous completion or withdrawal from this study
Unwillingness or inability to follow up per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - Up to 12 weeks or as determined by treatment needs
Participants in the ClotTriever Intervention Arm receive mechanical thrombectomy using the ClotTriever System to restore vessel patency. Participants in the Conservative Medical Management Arm receive anticoagulation therapy to manage deep vein thrombosis.
1 procedure visit plus regular follow-up visits during treatment
Follow-up
Duration - Up to 180 days (+-14 days)
Participants are monitored for clinical outcomes and severity of post-thrombotic syndrome after treatment completion.
Follow-up visits at approximately 10 days and 180 days post-treatment
Trial Site Locations
Total: 64 locations
1
Honor Health
Scottsdale, Arizona, United States, 85258
Actively Recruiting
2
Pima Heart and Vascular
Tucson, Arizona, United States, 85704
Actively Recruiting
3
UCI Medical Center
Orange, California, United States, 92868
Actively Recruiting
4
Vascular and Interventional Specialists of Orange County
Orange, California, United States, 92868
Actively Recruiting
5
Huntington Health
Pasadena, California, United States, 91105
Actively Recruiting
6
University Of Colorado
Denver, Colorado, United States, 80045
Actively Recruiting
7
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
8
MedStar Health Research Institution
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
9
Manatee Memorial Hospital
Bradenton, Florida, United States, 34208
Terminated
10
Baptist Health Research Institute
Jacksonville, Florida, United States, 32207
Actively Recruiting
11
Lakeland Vascular Institute
Lakeland, Florida, United States, 33805
Terminated
12
HCA Florida Largo Hospital
Largo, Florida, United States, 33770
Actively Recruiting
13
Sarasota Memorial Hospital
Sarasota, Florida, United States, 34239
Actively Recruiting
14
BayCare Health System
Tampa, Florida, United States, 33607
Actively Recruiting
15
Memorial Health University Medical Center
Savannah, Georgia, United States, 31404
Terminated
16
Community Healthcare System
Munster, Indiana, United States, 46321
Terminated
17
St. Elizabeth Edgewood
Edgewood, Kentucky, United States, 41017
Terminated
18
University of Maryland
Baltimore, Maryland, United States, 21201
Actively Recruiting
19
McLaren Healthcare
Bay City, Michigan, United States, 48708
Actively Recruiting
20
Henry Ford Health
Detroit, Michigan, United States, 48202
Actively Recruiting
21
MyMichigan Medical Center
Midland, Michigan, United States, 48670
Actively Recruiting
22
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
23
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, United States, 64131
Terminated
24
St. Louis University
St Louis, Missouri, United States, 63104
Actively Recruiting
25
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States, 89102
Actively Recruiting
26
Cooper University Hospital
Camden, New Jersey, United States, 08103
Actively Recruiting
27
Holy Name Medical Center
Teaneck, New Jersey, United States, 07666
Terminated
28
Northwell Health
Bay Shore, New York, United States, 11706
Actively Recruiting
29
NYP-Brooklyn Methodist
Brooklyn, New York, United States, 11215
Actively Recruiting
30
SUNY, The University at Buffalo
Buffalo, New York, United States, 14203
Terminated
31
NYU Langone Medical Center
New York, New York, United States, 10016
Actively Recruiting
32
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
33
Mission Health
Asheville, North Carolina, United States, 28801
Terminated
34
Mercy Health - The Heart Institute
Cincinnati, Ohio, United States, 45211
Terminated
35
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
36
Saint Francis Hospital
Tulsa, Oklahoma, United States, 74136
Actively Recruiting
37
Allegheny St. Vincent Hospital
Erie, Pennsylvania, United States, 16544
Actively Recruiting
38
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
39
Allegheny General Health Research Network
Pittsburgh, Pennsylvania, United States, 15212
Actively Recruiting
40
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
41
Prisma Health Upstate
Greenville, South Carolina, United States, 29615
Terminated
42
Spartanburg Medical Center
Spartanburg, South Carolina, United States, 29303
Actively Recruiting
43
Lexington Medical Center
West Columbia, South Carolina, United States, 29169
Rationale and design of the DEFIANCE study: A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosis.
Steven D Abramowitz, Xhorlina Marko, Donna D'Souza...